Precision medicine delivers personalized cancer care based on an individual’s genomics, lifestyle, and environment. Precision medicine implements the use of biomarkers, molecular testing, and targeted therapies to tailor treatment plans that address the unique needs of every patient.
Helping to bring personalized cancer care into focus, ACCC transforms complex science into clear and actionable education that brings clarity to patient care decisions. From essential knowledge on cancer screening updates to clinically impactful biomarker testing and new cancer diagnostic assay development, the ACCC Precision Medicine Library has fundamental resources that match the professional needs and preferred learning styles of the multidisciplinary cancer team.
ACCC develops targeted educational resources and programs that help multidisciplinary cancer care teams stay up to date on the latest advancements in cancer diagnostics. This includes resources on subjects including biomarkers, measurable residual disease (MRD) testing, multi-cancer early detection, and pathology.
ACCC develops targeted educational resources and programs that help multidisciplinary cancer care teams stay up to date on the latest advancements in cancer diagnostics. This includes resources on subjects including biomarkers, measurable residual disease (MRD) testing, multi-cancer early detection, and pathology.
ACCC offers a variety of educational and practical resources to help community programs achieve a more coordinated care experience for their patients. This includes projects and resources on eliminating disparities in precision medicine, genetic counseling, and precision medicine stewardship.
During the HOPA 2026 annual conference, ACCC brought together a small group of oncology pharmacists for a practical, candid conversation about challenges with the implementation of bispecific antibodies that was deeply grounded in real-world experience and what it takes to operationalize care.
In recognition of Bladder Health Awareness Month, ACCC shares the results of a recent quality improvement study, which provides impactful steps cancer centers can take to mitigate disparities in bladder cancer.
ACCC is excited to share its new provider resources for TIL cell therapy, including a referral readiness checklist, patient pathway guide, and white paper with tangible steps for improving access.
Advanced practice providers (APPs) are essential members of the cancer care team with roles that vary depending on institutional policies and state regulations. Empowering APPs to work at the top of their scope leads to stronger care delivery.
In this episode, CANCER BUZZ speaks with Laura Kuzma, MSW, admin administrative director of FirstHealth Cancer Center and Oncology Services at FirstHealth Moore Regional Hospital, about the real-world lessons she has learned about governance considerations, ramp-up strategies, and workflows. She shares the importance of proactively building workflows, readiness plans, and cross-team communication pathways to safely operationalize BsAb therapy.
In this episode, CANCER BUZZ speaks with Meagan O’Neill, MS, executive director of ACCC, about the 2025 ACCC Impact Report, highlighting advancements in financial advocacy, patient-centered care for Veterans with cancer, and access to cutting-edge therapies like CAR T-cell therapy.
Tumor-infiltrating lymphocyte (TIL) cell therapy is a promising option for patients with advanced melanoma, but logistical and referral challenges can be a barrier to care. In this episode, CANCER BUZZ speaks with Lilit Karapetyan, MD, MS, FACP, medical oncologist at Moffit Cancer Center and Research Institute, an authorized treatment center (ATC) for TIL cell therapy, and Raju Vaddepally, MD, hematologist-oncologist at Florida Cancer Specialists, a non-ATC, about the referral process. Both guests discuss the relationship between their cancer programs, offering actionable tips on how to streamline the identification and referral of melanoma patients for TIL therapy across institutions.
CAR T-cell therapy is a potentially life-saving treatment for patients with certain hematologic malignancies. Yet, the logistical challenges and the need for specialized management of adverse events have limited its availability in community settings. In this episode, CANCER BUZZ speaks with Jeremy M. Pantin, MD, FACP, clinical director of the Adult Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, part of the Sarah Cannon Transplant and Cellular Therapy Network. Dr. Pantin discusses the cancer center’s community-based, outpatient model, impact on outcomes for patients with hematologic malignancies, and shares his perspective on future changes needed to help further expand access to CAR T-cell therapy.
Gain insights on reshaping multidisciplinary cancer care team workflows to enable laboratory professionals to improve biomarker testing efficiency.
While recent advances in precision medicine have substantially changed the management of lung cancer, care must be taken to ensure that these advances do not worsen health disparities. This study included a case component that divided overall respondents into two cohorts to observe how patient characteristics, such as age, socio-economic status, race/ethnicity, and health literacy, affected the likelihood of ordering biomarker testing.
This article explores the exciting potential for pharmacists in the cardio-oncology setting, where their knowledge of oncolytic therapies, drug interactions, and toxicity management proves integral to patient care.
ACCC shares how Sanford Health introduced its own “precision medicine steward” through the development of a pilot Oncology Nurse Navigator, Genomics (ONNG) role, which has improved coordination of its biomarker testing program.
Presented at The American Society for Clinical Pathology (ASCP) 2022 Annual Meeting, September 7-9, 2022.
Presented at the 2021 ASCO Quality Care Symposium, September 24 - 25, 2021.
Presented at the IASLC 2021 World Conference on Lung Cancer, September 8-14, 2021
Presented at the SITC Annual Conference.